Sirona Biochem Corp. (TSXV:SBM, FSE:ZSB, OTC:SRBCF) has moved its AGM to 9:00am (Pacific Time) on Friday, May 22, 2020.
Sirona Biochem Corp. (TSXV:SBM, FSE:ZSB, OTC:SRBCF) (the “Company” or “Sirona Biochem”) announces that the Board of Directors of the Company have considered current COVID-19 public health restrictions and determined it to be in the best interests of the Company and its shareholders to adjourn the date to hold the Company’s annual general meeting (“AGM”), originally scheduled for Friday, April 24, 2020, to 9:00 a.m. (Pacific Time) on Friday, May 22, 2020. All other aspects of the AGM remain the same as published in the AGM proxy materials posted at www.sedar.com.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona Biochem’s subsidiary lab, TFChem, specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential. Sirona Biochem’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments.
For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of
the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information regarding this press release, please contact:
Investor Enquiries: Jonathan Williams, Managing Director, Momentum PR, Phone: 1.450.332.6939,
Email: email@example.com; Corporate Enquiries: Dr. Howard Verrico, CEO, Chairman of the
Board, Sirona Biochem Corp., Phone: 1.604.641.4466, Email: firstname.lastname@example.org
Forward Looking Information
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.